|
| Tuesday, January 28, 2025 |
|
|
FDA Approves LEQEMBI (lecanemab-irmb) IV Maintenance Dosing for the Treatment of Early Alzheimer's Disease |
| Eisai Co., Ltd. and Biogen Inc. announced today that the U.S. Food and Drug Administration (FDA) has approved the Supplemental Biologics License Application (sBLA) for once every four weeks lecanemab-irmb (U.S. brand name: LEQEMBI) intravenous (IV) maintenance dosing. more info >> |
|
| Wednesday, January 22, 2025 |
|
|
Eisai Listed as a Global 100 Most Sustainable Corporation for The Ninth Time Highest Ranked Global Pharmaceutical Company |
| Eisai Co., Ltd. announced today that it has been listed in the 2025 Global 100 Most Sustainable Corporations in the World (Global 100), a global ranking by Canada-based media and investment advisory company, Corporate Knights, Inc. more info >> |
|
|
エーザイ、「世界で最も持続可能な100社」に9回目の選定 |
| エーザイ株式会社（本社：東京都、代表執行役CEO：内藤晴夫）は、このたび、カナダのメディア・投資調査会社コーポレートナイツ社が選定する「2025年 世界で最も持続可能な100社」（2025 Global 100 Most Sustainable Corporations in the World、以下「Global 100」）に選定されましたのでお知らせします。 more info >> |
|
| Wednesday, January 15, 2025 |
|
|
FDA Accepts LEQEMBI (lecanemab-irmb) Biologics License Application for Subcutaneous Maintenance Dosing for the Treatment of Early Alzheimer's Disease |
| Eisai Co., Ltd. and Biogen Inc. announced today that the U.S. Food and Drug Administration (FDA) has accepted Eisai's Biologics License Application (BLA) for lecanemab-irmb (U.S. brand name: LEQEMBI) subcutaneous autoinjector (SC-AI) for weekly maintenance dosing. more info >> |
|
| Tuesday, January 14, 2025 |
|
|
エーザイとバイオジェン・インク、早期アルツハイマー病治療剤「レケンビ(R)」の皮下注射製剤維持投与に関する 生物製剤承認申請を米国FDAが受理 |
| エーザイ株式会社（本社：東京都、代表執行役 CEO：内藤晴夫、以下 エーザイ）とバイオジェン・インク（Nasdaq：BIIB、本社：米国マサチューセッツ州ケンブリッジ、CEO：Christopher A. Viehbacher、以下 バイオジェン）は、このたび、ヒト化抗ヒト可溶性アミロイド β（Aβ）凝集体モノクローナル抗体「レケンビ(R)」（一般名：レカネマブ）について、皮下注射オートインジェクター（SC-AI）による維持投与（週一回投与）に関する生物製剤承認申請（BLA）が、米国食品医薬品局（FDA）に受理されたことをお知らせします。 more info >> |
|
| Tuesday, January 7, 2025 |
|
|
Elucidation of part of the Mechanism by which Lecanemab Slows the Progression of Alzheimer's Disease |
| A collaborative research group led by Professor Kenjiro Ono of the Institute of Medical, Pharmaceutical and Health Sciences, Kanazawa University, and Eisai Co., Ltd. more info >> |
|
|
金沢大とエーザイ、レカネマブがアルツハイマー病の病態進行を抑制するメカニズムの一端を解明 |
| more info >> |
|
| Monday, December 23, 2024 |
|
|
Fujirebio and Eisai Enter into Memorandum of Understanding for Joint Research and Social Implementation of Blood-based Biomarkers in the Field of Neurodegenerative Diseases |
| Fujirebio Holdings, Inc., a wholly-owned subsidiary of H.U. Group Holdings, Inc., and Eisai Co., Ltd. announced today that they have entered into a memorandum of understanding for the joint research and social implementation of novel blood-based biomarkers in the field of neurodegenerative diseases. more info >> |
|
| Wednesday, December 11, 2024 |
|
|
Eisai's "URECE(R)" (Dotinurad) Approved in China for Gout Patients with Hyperuricemia |
| Eisai Co., Ltd. announced today that it has received approval for "URECE(R)" (generic name: dotinurad) from the National Medical Products Administration in China as a treatment for gout patients with hyperuricemia. more info >> |
|
| Thursday, December 5, 2024 |
|
|
"LEQEMBI" (Lecanemab) Approved for the Treatment of Early Alzheimer's Disease in Mexico |
| Eisai Co., Ltd. and Biogen Inc. announced today that the Federal Commission forthe Protection Against Sanitary Risk (COFEPRIS) in Mexico has approved humanized anti-soluble aggregated amyloid-beta (Abeta) monoclonal antibody "LEQEMBI" (lecanemab) for the treatment of early Alzheimer's disease (AD). more info >> |
|
|
|
|
